Gufic BioSciences Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 15 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹4.0K Cr

The company targets a minimum 15% growth in sales/revenue for FY 2026-27 and FY 2027-28, with an optimistic aim of up to 20% or more depending on regulatory approvals and market factors. FY '27 revenue growth targeted at a **minimum of 15%**, with potential to reach **20% or more** depending on regulatory approvals and market factors (Page 14, 6).

From Gufic BioSciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹432

Market Cap

₹4.0K Cr

P/E Ratio

62.6

How does Gufic BioSciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare Gufic BioSciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Gufic BioSciences Ltd — Quarterly revenue & net profit

Revenue Net Profit

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹231 Cr, net profit ₹12 Cr.

Full financials →

📊 Revenue & Sales Performance

→The company targets a minimum 15% growth in sales/revenue for FY 2026-27 and FY 2027-28, with an optimistic aim of up to 20% or more depending on regulatory approvals and market factors.
→International business (exports) is expected to ramp up notably from Q2/Q3 FY 2026 with the completion of audits and approvals (e.g., EU GMP certificate by March/April 2026).
→The Indore plant ramp-up will contribute significantly, with production utilization projected to hit 50% by Q4 FY 2026-27 and further growth thereafter.
→Export revenues from Indore are expected to start materializing in Q3/Q4 FY 2026, especially across Europe, Southeast Asia, and regulated markets.
→Domestic branded business growth is seen around 8% due to correction in debtor control and divestment in certain divisions.
→Botulinum toxin segment is growing strongly (22-25% YoY) with potential for further category expansion.
→EBITDA margins are expected to improve with increasing capacity utilization, reaching up to 20-21% beyond 75% utilization.

📈 Profitability & Margins

→FY '27 revenue growth targeted at a **minimum of 15%**, with potential to reach **20% or more** depending on regulatory approvals and market factors (Page 14, 6).
→EBITDA from the Indore plant expected to break even by **Q4 FY '25-'26** and become cash flow positive post FY '27 (Page 11).
→Export revenues from Indore anticipated to start significantly contributing from **Q3/Q4 FY '26** with EU GMP and other regulatory approvals (Page 11, 6).
→Debt levels expected to stay around **INR 375 crores till March '27**, then begin to reduce with term loan prepayment starting FY '28 (Page 16).
→Operating expenses, including employee costs, projected to rise moderately due to increments but stabilize post-ramp-up (Page 7).
→Margins likely to maintain with stable depreciation/interest costs (~INR35-36 crores) in FY '27 (Page 16).
→Overall outlook is cautious but optimistic, factoring in working capital control and regulatory uncertainties.

🏗️ Capital Expenditure Plans

- Investment in Selvax, a cancer vaccine therapy for solid tumors, with over $150,000 invested over the last 4-5 years; this is a long-term, start-up-like investment with promising animal-level proof of concept and ongoing progress such as outsourcing final construct to Syngene. - Indore plant expansion with term loans taken for capacity ramp-up; expected to reach 50% utilization by Q4 FY '26-'27 and contribute to export revenue starting Q3/Q4 FY '26. - Investments in technology transfer projects like GLP-1 validation batches at Indore, enhancing production capabilities. - Implementation of Marg software in stockists to strengthen data control and optimize working capital. - No fresh major recruitments planned; focus on annual increments and productivity improvements. - Ongoing R&D and validation expenses as recurring costs for at least 1.5 to 2 years associated with product and regulatory development. Overall, capex focus is on capacity expansion, strategic long-term biotech investments, and digital infrastructure for sales and working capital management.

💰 Fundraising & Capital Structure

→Current Debt: Around INR 375 crores (term loan for Indore plant + working capital loans).
→Debt Level Outlook: Expected to remain at INR 375 crores through FY '27.
→Deleveraging Plan: No prepayment of term loan until after FY '27; prepayment will start from FY '28 onwards.
→Working Capital: Managed largely through internal accruals rather than additional borrowing.
→No mention of new equity fundraising or additional debt plans in the near term.
→Focus is on internal cash flow and operational efficiencies rather than fresh fundraising for the next 2-3 years.

📋 Order Book & Pipeline

→The current order book at Indore (Unit-2) stands at around INR150 crores to INR155 crores.
→Management aims to reduce this order book to around INR80 crores to INR90 crores.
→The reduction target is to bring the order book from a 90-day window to a 60-day window.
→Navsari orders for exports to countries like the U.K., Portugal, and Brazil are also ramping up.
→The export division has shown growth of approximately 40%, though the base is smaller (~INR120 crores).
→Validation batches for GLP-1 products from Indore were completed in January, with testing ongoing in February.
→Overall, there is a positive outlook on the order inflow and its impact on revenue going forward.

Key Metrics

What Gufic BioSciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Gufic BioSciences Ltd Q3 FY26 results?

What is Gufic BioSciences Ltd share price analysis?

Gufic BioSciences Ltd currently shows a neutral. The stock trades at a P/E of 62.6 with a market cap of ₹3,955 Cr. Investors should review the full earnings analysis for detailed insights.

Is Gufic BioSciences Ltd planning capital expenditure?

Investment in Selvax, a cancer vaccine therapy for solid tumors, with over $150,000 invested over the last 4-5 years; this is a long-term, start-up-like investment with promising animal-level proof of concept and ongoing progress such as outsourcing final construct to Syngene.

Keep Gufic BioSciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.